share_log

Avenue Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Robert Davidow(2.9%)

Avenue Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Robert Davidow(2.9%)

Avenue Therapeutics | SC 13G/A：超過5%持股股東披露文件(修正)-Robert Davidow(2.9%)
美股sec公告 ·  05/02 16:06
Moomoo AI 已提取核心訊息
Robert Davidow has filed an amendment with the Securities and Exchange Commission, indicating a change in his ownership stake in Avenue Therapeutics, Inc. According to the Schedule 13G/A filed on May 2, 2024, Davidow now owns less than 5% of the company's common stock, specifically 17,206 shares, which represents 2.9% of the class. This filing is an update to the previous Schedule 13G filings made in November and December 2023. The shares are held in various forms, including individual ownership, joint accounts with his wife, trusts for his children, and accounts over which he has shared dispositive authority. The reporting also reflects the impact of a 75-for-1 reverse stock split that took effect on April 26, 2024. Davidow has disclaimed beneficial ownership of the shares except to the extent of his pecuniary interest and has certified that the shares were not acquired for the purpose of changing or influencing the control of the issuer.
Robert Davidow has filed an amendment with the Securities and Exchange Commission, indicating a change in his ownership stake in Avenue Therapeutics, Inc. According to the Schedule 13G/A filed on May 2, 2024, Davidow now owns less than 5% of the company's common stock, specifically 17,206 shares, which represents 2.9% of the class. This filing is an update to the previous Schedule 13G filings made in November and December 2023. The shares are held in various forms, including individual ownership, joint accounts with his wife, trusts for his children, and accounts over which he has shared dispositive authority. The reporting also reflects the impact of a 75-for-1 reverse stock split that took effect on April 26, 2024. Davidow has disclaimed beneficial ownership of the shares except to the extent of his pecuniary interest and has certified that the shares were not acquired for the purpose of changing or influencing the control of the issuer.
羅伯特·戴維多已向美國證券交易委員會提交了一項修正案，表示他在Avenue Therapeutics, Inc.的所有權發生了變化。根據2024年5月2日提交的附表13G/A，戴維多現在擁有該公司不到5％的普通股，特別是17,206股股票，佔該類別的2.9％。本文件是對先前於2023年11月和12月提交的附表13G申請的更新。股份以各種形式持有，包括個人所有權、與妻子的聯名賬戶、子女信託以及他共享處置權的賬戶。該報告還反映了2024年4月26日生效的75比1反向股票拆分的影響。Davidow已放棄對股票的實益所有權，但其金錢權益除外，並已證明收購這些股份不是爲了改變或影響發行人的控制權。
羅伯特·戴維多已向美國證券交易委員會提交了一項修正案，表示他在Avenue Therapeutics, Inc.的所有權發生了變化。根據2024年5月2日提交的附表13G/A，戴維多現在擁有該公司不到5％的普通股，特別是17,206股股票，佔該類別的2.9％。本文件是對先前於2023年11月和12月提交的附表13G申請的更新。股份以各種形式持有，包括個人所有權、與妻子的聯名賬戶、子女信託以及他共享處置權的賬戶。該報告還反映了2024年4月26日生效的75比1反向股票拆分的影響。Davidow已放棄對股票的實益所有權，但其金錢權益除外，並已證明收購這些股份不是爲了改變或影響發行人的控制權。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息